Intec Pharma Ltd.
Latest From Intec Pharma Ltd.
The Japanese firm's original 2007 NDA was rejected in 2008 but it kept faith in the drug, now approved as an adjunct to levodopa/carbidopa. At least one competitor is waiting in the wings.
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
Appointments: Astellas, MorphoSys, AZTherapies, Sigilon Therapeutics, Intec Pharma And Tenaya Therapeutics
This week's round-up includes promotions at Astellas, new CSOs at MorphoSys and Tenaya, a new president and CMO at AZTherapies, new directors at BioScience Managers, plus board changes at Intec and Sigilon.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- Middle East
- Parent & Subsidiaries
- Intec Pharma Ltd.
- Senior Management
Jeffery A Meckler, CEO & Vice Chmn.
Nir Sassi, CFO
Nadav Navon, PhD, COO
Walt A Linscott, Chief Administrative Officer
R. Michael Gendreau, MD, PhD, CMO
- Contact Info
Intec Pharma Ltd.
Phone: (972) (2) 586-4657
12 Hartom St.
P.O. Box 45219 Jerusalem, 91450
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.